Li P, et al. - Among US Medicare beneficiaries with asthma who initiated omalizumab therapy, researchers assessed the characteristics and treatment patterns as well as factors related to discontinuation and adherence to omalizumab. In this retrospective claims database analysis, omalizumab continuation and adherence to this therapy was reported among over 60% of Medicare patients with asthma during a 12-month follow-up. Factors related to treatment adherence and discontinuation were patient age, low-income subsidy (LIS) status, and the numbers of evaluation and management physician visits. Significantly lower odds of discontinuation and higher odds of adherence were reported in patients aged 65–69 and 70–74 years vs those aged ≥ 80 years. Lower odds of discontinuation and higher odds of adherence were reported in non-LIS patients vs patients receiving LIS. Also, lower odds of discontinuation and higher odds of adherence were reported in relation to greater numbers of pre-index evaluation and management physician visits and comorbid rhinitis.